JNCI Journal of the National Cancer Institute · 2017 · 134 citations · 15 references
MedicineOncologyPharmacologyChemotherapyOncology PharmacotherapyPain ManagementAdverse Effects Of ChemotherapyBreast Cancer PharmacotherapyMedication Side Effect ManagementPeripheral Neuropathy ManagementCancer-related Neuropathic PainChemotherapy Medication SafetyChemotherapy Toxicity PreventionChemotherapy-induced FatigueDrug-induced Peripheral NeuropathyNeuropathic ChangesSensitivityTaxane Therapy
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting and disabling side effect of taxane anticancer agents. We prospectively evaluated the efficacy of cryotherapy for CIPN prevention. Methods: Breast cancer patients treated weekly with paclitaxel (80 mg/m2 for one hour) wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion. Symptoms on the treated sides were compared with those on the untreated (nondominant) sides. The primary end point was CIPN incidence assessed by changes in tactile sensitivity from pretreatment baseline in a monofilament test at a cumulative dose of 960 mg/m2. We also assessed thermosensory deficits, subjective symptoms (Patient Neuropathy Questionnaire [PNQ]), manipulative dexterity, and the time to events and hazard ratio by PNQ. All statistical tests were two-sided. Results: Among the 40 patients, four did not reach the cumulative dose (due to the occurrence of pneumonia, severe fatigue, severe liver dysfunction, and macular edema), leaving 36 patients for analysis. None dropped out due to cold intolerance. The incidence of objective and subjective CIPN signs was clinically and statistically significantly lower on the intervention side than on the control (hand: tactile sensitivity = 27.8% vs 80.6%, odds ratio [OR] = 20.00, 95% confidence interval [CI] = 3.20 to 828.96, P < .001; foot: tacile sensitivity = 25.0% vs 63.9%, OR = infinite, 95% CI = 3.32 to infinite, P < .001; hand: warm sense = 8.8% vs 32.4%, OR = 9.00, 95% CI = 1.25 to 394.48, P = .02; foot: warm sense: 33.4% vs 57.6%, OR = 5.00, 95% CI = 1.07 to 46.93, P = .04; hand: PNQ = 2.8% vs 41.7%, OR = infinite, 95% CI = 3.32 to infinite, P < .001; foot: PNQ = 2.8% vs 36.1%, OR = infinite, 95% CI = 2.78 to infinite, P < .001; hand: hazard ratio [HR] = 0.13, 95% CI = 0.05 to 0.34; foot: HR = 0.13, 95% CI = 0.04 to 0.38, dexterity mean delay = -2.5 seconds, SD = 12.0 seconds, vs + 8.6 seconds, SD = 25.8 seconds, P = .005). Conclusions: Cryotherapy is useful for preventing both the objective and subjective symptoms of CIPN and resultant dysfunction.
15
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Joseph A. Sparano, Molin Wang, Silvana Martino et al. · New England Journal of Medicine · 2008 · 1K citations · Full text
Medicine, Oncology, Pharmacology +13
Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi et al. · Supportive Care in Cancer · 2009 · 198 citations
Pharmacy, Oncology, Pharmacology +17